Date Range
Date Range
Date Range
LaunchCyte LLC was founded in 2000 to bring to market unique university technologies. Today, we have a portfolio of five companies that offer solutions in healthcare, lighting and display industries. LaunchCyte LLC was founded in 2000 to bring to market unique university technologies. Today, we have a portfolio of five companies that offer solutions in healthcare, lighting and display industries.
Modeling and Simulation for Pharmaceutical R and D. Your Modeling and Simulation partner. Vantage helps pharmaceutical companies build in silico models of complex physiological systems in order to simulate clinical outcomes, and use that knowledge to make optimal decisions in the drug development process. Vantage Research develops and uses mathematical models of physiology to aid decision-making in the process of drug development. Several high-value decisions need to be taken when taking a compound from .
LaunchCyte
2403 Sidney St. Suite 200
Pittsburgh, Pennsylvania, 15203
United States
LaunchCyte
2403 Sidney St. Suite 200
Pittsburgh, Pennsylvania, 15203
United States
, and the symptoms that result from any of the above, including learning disabilities, migraines, asthma, hypoglycemia, etc. Essays, how-to, medical information, and other original writings.
Immunex Pro - Immune Enhancing Protein. Wednesday, September 16, 2009. Is a specially designed whey protein which was developed from years of scientific research. Is the only whey protein that duplicates the special whey protein used in numerous published research studies. It is developed using patented techniques to prevent the whey fractions and amino acid from denaturing. Enhances optimal concentrations of glutathione in the body. Glutathione is a vital immune system cell component, a.
Neutrophils attracted to unique fungal carbohydrate. Fungal carbohydrate is conjugated to cancer-targeting monoclonal antibodies. Tumor cells recognized by mAbXcite antibodies. Neutrophils attracted to mAbXcite antibodies. Neutrophils lead to destruction of tumor cells. ImmuneXcite Presents New Preclinical Data at AACR Demonstrating Ability of its Novel Cancer Immunotherapy Approach to Activate a Potent and Precise T-Cell Attack on Tumors.
Enhanced and personalized management of sepsis. Powered by host response-based molecular diagnostics. Revolutionary and rapid blood biomarker technology to aid clinicians in managing patients with sepsis or suspected of sepsis. The solution is in our genes. For a series of video interviews highlighting the need for faster diagnosis of sepsis and how SeptiCyte can help.